Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.
CRP
ECOG
atezolizumab
chemo-immunotherapy
immune-checkpoint inhibitor
immunotherapy
men and women
nivolumab
pembrolizumab
response prediction
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Dec 2021
24 Dec 2021
Historique:
received:
22
11
2021
revised:
14
12
2021
accepted:
22
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
Men with non-small cell lung cancer (NSCLC) have a more favorable response to immune-checkpoint inhibitor (ICI) monotherapy, while women especially benefit from ICI-chemotherapy (CHT) combinations. To elucidate such sex differences in clinical practice, we retrospectively analyzed two cohorts treated with either ICI monotherapy (
Identifiants
pubmed: 35008255
pii: cancers14010093
doi: 10.3390/cancers14010093
pmc: PMC8750380
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Thorac Oncol. 2017 Jul;12(7):1109-1121
pubmed: 28461257
Lancet Oncol. 2021 Feb;22(2):198-211
pubmed: 33476593
Eur J Cancer. 2019 Jan;106:144-159
pubmed: 30528799
Cancers (Basel). 2020 Aug 17;12(8):
pubmed: 32824580
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Oncologist. 2018 Nov;23(11):1388-1390
pubmed: 30012876
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
JAMA Oncol. 2018 Feb 1;4(2):210-216
pubmed: 29270615
N Engl J Med. 2018 May 24;378(21):1999-2009
pubmed: 29791813
J Clin Oncol. 2007 Feb 10;25(5):472-8
pubmed: 17290054
JAMA Oncol. 2019 Apr 1;5(4):529-536
pubmed: 30605213
Semin Cancer Biol. 2018 Oct;52(Pt 2):269-277
pubmed: 29782924
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Lung Cancer. 2019 Aug;134:59-65
pubmed: 31319996
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
J Clin Med. 2019 Jul 10;8(7):
pubmed: 31295966
Target Oncol. 2019 Dec;14(6):707-717
pubmed: 31654203
Front Oncol. 2020 Feb 18;10:137
pubmed: 32133288
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Surg Oncol. 2018 Mar;27(1):88-94
pubmed: 29549910
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lancet Oncol. 2017 Jul;18(7):895-903
pubmed: 28551359
J Thorac Oncol. 2020 Feb;15(2):166-169
pubmed: 32127183
Clin Cancer Res. 2021 Aug 1;27(15):4311-4324
pubmed: 34016641
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Thorac Oncol. 2016 Sep;11(9):1411-22
pubmed: 27296106
Cancer Med. 2020 Feb;9(4):1383-1391
pubmed: 31880861
Molecules. 2019 Sep 04;24(18):
pubmed: 31487832
J Natl Cancer Inst. 2019 Aug 1;111(8):772-781
pubmed: 31106827
Semin Immunopathol. 2019 Mar;41(2):133-135
pubmed: 30742253